Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Dhiraj Gupta , Serge Boveda Added: 2 years ago
In this video from Arrhythmia Academy's Journal Club, Dr Dhiraj Gupta (Liverpool Heart and Chest NHS Foundation Trust, UK) is joined by Dr Serge Boveda (Clinique Pasteur Toulouse, FR) to discuss methods and approaches to pulsed-field ablation (PFA) of recurrent right atrial tachycardia. Dr Boveda delivers a short presentation, outlining a difficult case in which PFA was implemented to treat a 68… View more
Author(s): Alexis Cutchins , Svetlana Blitshteyn , Rebecca Steinberg Added: 1 year ago
Postural Orthostatic Tachycardia Syndrome (POTS) is a heterogenous disorder that presents with positional tachycardia, amongst many other symptoms. Evidence for treatment options remains limited, and there are a multitude of associated conditions with overlapping symptoms which can make the diagnosis and management of POTS a difficult experience for providers and patients alike.This broadcast… View more
Author(s): Vivek Reddy Added: 6 months ago
HRS 25 - First-in-human data from the FIH VCAS trial suggests the FieldForce Ablation system can effectively create transmural ablation lesions in patients with scar-related ventricular tachycardia (VT), with an 80% freedom from VT and ventricular fibrillation rate at 6 months.We are joined by Dr Vivek Reddy (Mount Sinai Hospital, New York, US) to discuss the findings from the prospective, first… View more
Author(s): Vivek Reddy Added: 6 days ago
AHA 2025 - Dr Vivek Y Reddy (Icahn School of Medicine at Mount Sinai, New York, US) joins us to share findings from the PFA-SHAM study (NCT05717725) investigating pulsed field ablation (PFA) versus sham ablation to treat AF. Patients enrolled in the study underwent an electrophysiology study to ensure they had no concealed AV bypass tract or supraventricular tachycardia, and patients were then… View more
Author(s): Atul Verma Added: 1 week ago
AHA 2025 - Dr Atul Verma (McGill University Health Centre, Montreal, CA) joins us to share outcomes from OCEAN (NCT02168829). The prospective, open-label, randomised trial aimed to investigate ongoing oral anticoagulation with rivaroxaban 15 mg daily compared to antiplatelet therapy in patients with clinical stroke risk factors at least one year post-successful catheter ablation of AF, left… View more